Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Psychosocial interventions for cannabis use disorder.

Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L.

Cochrane Database Syst Rev. 2016 May 5;(5):CD005336. doi: 10.1002/14651858.CD005336.pub4. Review.

PMID:
27149547
2.

Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.

Levin FR, Mariani JJ, Pavlicova M, Brooks D, Glass A, Mahony A, Nunes EV, Bisaga A, Dakwar E, Carpenter KM, Sullivan MA, Choi JC.

Drug Alcohol Depend. 2016 Feb 1;159:53-60. doi: 10.1016/j.drugalcdep.2015.11.025.

3.

Vilazodone for cannabis dependence: A randomized, controlled pilot trial.

McRae-Clark AL, Baker NL, Gray KM, Killeen T, Hartwell KJ, Simonian SJ.

Am J Addict. 2016 Jan;25(1):69-75. doi: 10.1111/ajad.12324.

4.

Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

McRae-Clark AL, Baker NL, Gray KM, Killeen TK, Wagner AM, Brady KT, DeVane CL, Norton J.

Drug Alcohol Depend. 2015 Nov 1;156:29-37. doi: 10.1016/j.drugalcdep.2015.08.013.

5.

Crude estimates of cannabis-attributable mortality and morbidity in Canada-implications for public health focused intervention priorities.

Fischer B, Imtiaz S, Rudzinski K, Rehm J.

J Public Health (Oxf). 2016 Mar;38(1):183-8. doi: 10.1093/pubmed/fdv005.

6.
7.

Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network.

McClure EA, Sonne SC, Winhusen T, Carroll KM, Ghitza UE, McRae-Clark AL, Matthews AG, Sharma G, Van Veldhuisen P, Vandrey RG, Levin FR, Weiss RD, Lindblad R, Allen C, Mooney LJ, Haynes L, Brigham GS, Sparenborg S, Hasson AL, Gray KM.

Contemp Clin Trials. 2014 Nov;39(2):211-23. doi: 10.1016/j.cct.2014.08.011.

8.

Evidence based psychosocial interventions in substance use.

Jhanjee S.

Indian J Psychol Med. 2014 Apr;36(2):112-8. doi: 10.4103/0253-7176.130960. Review.

9.

Behavioral therapies for treatment-seeking cannabis users: a meta-analysis of randomized controlled trials.

Davis ML, Powers MB, Handelsman P, Medina JL, Zvolensky M, Smits JA.

Eval Health Prof. 2015 Mar;38(1):94-114. doi: 10.1177/0163278714529970.

10.

Project reduce: reducing alcohol and marijuana misuse: effects of a brief intervention in the emergency department.

Woolard R, Baird J, Longabaugh R, Nirenberg T, Lee CS, Mello MJ, Becker B.

Addict Behav. 2013 Mar;38(3):1732-9. doi: 10.1016/j.addbeh.2012.09.006.

11.

12-month follow-up of an exploratory 'brief intervention' for high-frequency cannabis users among Canadian university students.

Fischer B, Jones W, Shuper P, Rehm J.

Subst Abuse Treat Prev Policy. 2012 Apr 26;7:15. doi: 10.1186/1747-597X-7-15.

12.

Prenatal tobacco, marijuana, stimulant, and opiate exposure: outcomes and practice implications.

Minnes S, Lang A, Singer L.

Addict Sci Clin Pract. 2011 Jul;6(1):57-70. Review.

13.

Generalizability of clinical trials for cannabis dependence to community samples.

Okuda M, Hasin DS, Olfson M, Khan SS, Nunes EV, Montoya I, Liu SM, Grant BF, Blanco C.

Drug Alcohol Depend. 2010 Sep 1;111(1-2):177-81. doi: 10.1016/j.drugalcdep.2010.04.009.

14.

[Pharmacological and psychosocial interventions for cannabis use disorders].

Budney AJ, Vandrey RG, Stanger C.

Rev Bras Psiquiatr. 2010 May;32 Suppl 1:S46-55. Review. Portuguese.

15.

A placebo-controlled trial of buspirone for the treatment of marijuana dependence.

McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, Wahlquist AE, Simpson SA, Brady KT.

Drug Alcohol Depend. 2009 Nov 1;105(1-2):132-8. doi: 10.1016/j.drugalcdep.2009.06.022.

16.

Cocaine dependence and concurrent marijuana use: a comparison of clinical characteristics.

Lindsay JA, Stotts AL, Green CE, Herin DV, Schmitz JM.

Am J Drug Alcohol Abuse. 2009;35(3):193-8. doi: 10.1080/00952990902933860.

17.

Candidate genes for cannabis use disorders: findings, challenges and directions.

Agrawal A, Lynskey MT.

Addiction. 2009 Apr;104(4):518-32. doi: 10.1111/j.1360-0443.2009.02504.x. Review.

18.

A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence.

Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR.

Am J Addict. 2009 Jan-Feb;18(1):53-64. doi: 10.1080/10550490802408936.

19.

Marijuana neurobiology and treatment.

Elkashef A, Vocci F, Huestis M, Haney M, Budney A, Gruber A, el-Guebaly N.

Subst Abus. 2008;29(3):17-29. doi: 10.1080/08897070802218166. Review.

20.

Stress-related factors in cannabis use and misuse: implications for prevention and treatment.

Hyman SM, Sinha R.

J Subst Abuse Treat. 2009 Jun;36(4):400-13. doi: 10.1016/j.jsat.2008.08.005. Review.

Supplemental Content

Support Center